(Press-News.org) DENVER, March 23, 2015 -- Saccharin, the artificial sweetener that is the main ingredient in Sweet 'N Low®, Sweet Twin® and Necta®, could do far more than just keep our waistlines trim. According to new research, this popular sugar substitute could potentially lead to the development of drugs capable of combating aggressive, difficult-to-treat cancers with fewer side effects.
The finding will be presented today at the 249th National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society. The meeting features nearly 11,000 reports on new advances in science and other topics. It is being held here through Thursday.
"It never ceases to amaze me how a simple molecule, such as saccharin -- something many people put in their coffee everyday -- may have untapped uses, including as a possible lead compound to target aggressive cancers," says Robert McKenna, Ph.D., who is at the University of Florida. "This result opens up the potential to develop a novel anti-cancer drug that is derived from a common condiment that could have a lasting impact on treating several cancers."
The new work examines how saccharin binds to and deactivates carbonic anhydrase IX, a protein found in some very aggressive cancers. It is one of many driving factors in the growth and spread of such cancers in the breast, lung, liver, kidney, pancreas and brain. Carbonic anhydrase IX helps regulate pH in and around cancer cells, allowing tumors to thrive and potentially metastasize to other parts of the body. Because of this finding, the researchers wanted to develop saccharin-based drug candidates that could slow the growth of these cancers and potentially make them less resistant to chemo or radiation therapies.
Except for in the gastrointestinal tract, carbonic anhydrase IX is normally not found in healthy human cells. According to McKenna, this makes it a prime target for anti-cancer drugs that would cause little or no side effects to healthy tissue surrounding the tumor.
Unfortunately, there's a catch.
Carbonic anhydrase IX is similar to other carbonic anhydrase proteins that our bodies need to work properly. So far, finding a substance that blocks carbonic anhydrase IX without affecting the other ones has been elusive. And that's where saccharin -- ironically, once considered a possible carcinogen-- comes in.
In earlier work, scientists from a group led by Claudiu T. Supuran, Ph.D., at the University of Florence, Italy, discovered that saccharin inhibits the actions of carbonic anhydrase IX, but not the 14 other carbonic anhydrase proteins that are vital to our survival. Building on this finding, a team led by Sally-Ann Poulsen, Ph.D., at Griffith University, Australia, created a compound in which a molecule of glucose was chemically linked to saccharin. This small change had big effects. Not only did it reduce the amount of saccharin needed to inhibit carbonic anhydrase IX, the compound was 1,000 times more likely to bind to the enzyme than saccharin.
Using X-ray crystallography, McKenna and his students Jenna Driscoll and Brian Mahon have taken this work a step further by determining how saccharin binds to carbonic anhydrase IX, and how it or other saccharin-based compounds might be tweaked to enhance this binding and boost its anti-cancer treatment potential.
McKenna's team is currently testing the effects of saccharin and saccharin-based compounds on breast and liver cancer cells. If successful, these experiments could lead to animal studies.
INFORMATION:
A press conference on this topic will be held Tuesday, March 24, at 3:30 p.m. Mountain time in the Colorado Convention Center. Reporters may check-in at Room 104 in person, or watch live on YouTube http://bit.ly/ACSLiveDenver. To ask questions, sign in with a Google account.
The researchers acknowledge funding by the National Institutes of Health, the European Union and the Australian Research Council. The manufacturers of Sweet 'N Low® state that they did not fund this research.
The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With more than 158,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive news releases from the American Chemical Society, contact newsroom@acs.org.
Note to journalists: Please report that this research is being presented at a meeting of the American Chemical Society.
Follow us: Twitter | Facebook
Title
Saccharin and its carbohydrate-conjugate shows promise for isoform selective inhibition of Carbonic Anhydrase IX: a lead approach to anti-cancer drug development
Abstract
Carbonic anhydrase IX (CA IX) is a zinc metalloenzyme that is highly expressed in several aggressive cancer types and its expression has been linked to a poorer prognosis in patients. Inhibition of CA IX has shown to be advantageous in terms of reducing tumor cell proliferation, growth, and inducing chemo- and radiosensitivity in solid tumors. As such, CA IX has been characterized as an ideal anti-cancer target due to its minimal expression in normal human tissue and its physiochemical properties. Despite inhibition of CA IX showing great therapeutic promise, designing selective CA IX inhibitors has been challenging due to its high homology with other ubiquitously expressed human isoforms. Here we demonstrate that saccharin, the main additive in "Sweet N' Low", can be used as a lead compound for structure-based drug design of CA IX selective inhibitors. Furthermore we show how the linkage of a carbohydrate fragment to saccharin enhances CA IX inhibition by >1000-fold over other isoforms and provide insights into the structure-activity relationships of such compounds. This data presents a new class of CA IX inhibitors that will potentially aide in the treatment of several cancers.
DENVER, March 23, 2015 -- Squid are the ultimate camouflage artists, blending almost flawlessly with their backgrounds so that unsuspecting prey can't detect them. Using a protein that's key to this process, scientists have designed "invisibility stickers" that could one day help soldiers disguise themselves, even when sought by enemies with tough-to-fool infrared cameras.
The researchers will present their work today at the 249th National Meeting & Exposition of the American Chemical Society (ACS). ACS, the world's largest scientific society, is holding the meeting ...
DENVER, March 23, 2015 -- More than a year into Colorado's experiment legalizing marijuana, labs testing the plants are able for the first time to take stock of the drug's potency and contaminants -- and openly paint a picture of what's in today's weed. At the 249th National Meeting & Exposition of the American Chemical Society (ACS), one such lab will present trends -- and some surprises -- that its preliminary testing has revealed about the marijuana now on the market.
ACS, the world's largest scientific society, is holding the meeting here through Thursday. It features ...
Researchers from the University of Copenhagen are the first in the world to develop a secure way of measuring the important protein apo-M. This could prove relevant for research into diseases such as diabetes, arteriosclerosis and sclerosis.
For the first time, researchers from the University of Copenhagen have managed to develop a secure way of measuring the protein apo-M in our blood. The protein is interesting because it may prove important to research into diseases such as multiple sclerosis, arteriosclerosis and diabetes.
'We know that apo-M is of importance to ...
States that have expanded their Medicaid programs under the Affordable Care Act (ACA) are capturing an increased number of people with previously undiagnosed diabetes, allowing them to begin treatment earlier, potentially reducing complications and other negative outcomes, according to a study being published online today and in the May issue of Diabetes Care.
The release of the study coincides with the 5th anniversary of the ACA, which expanded Medicaid eligibility to reach nearly all non-elderly adults with incomes at or below 138 percent of the federal poverty level ...
Coral Gables, Fla. (March 23, 2015) - A new study shows that providing women with skills to manage stress early in their breast cancer treatment can improve their mood and quality of life many years later. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings suggest that women given the opportunity to learn stress management techniques during treatment may benefit well into survivorship.
At the turn of the century, 240 women with a recent breast cancer diagnosis participated in a randomized trial that tested the effects ...
Scientists have found that genetic changes in bowel tumours are linked to the way the body's immune system responds to the cancer, according to research published today (Monday) in the journal Oncoimmunology*.
For the first time, Cancer Research UK researchers at the University of Birmingham have found that certain genetic flaws in bowel cancer are more likely to trigger an immune response at the site of tumours, meaning that treatments to boost this immune response further could potentially be helpful for these patients.
Finding out what's happening in a cancer patient's ...
Climate change could accelerate the emergence of vector-borne diseases such as chikungunya, dengue fever, and West Nile virus in the UK, warn leading public health experts Dr Jolyon Medlock and Professor Steve Leach from the Emergency Response Department at Public Health England, writing in The Lancet Infectious Diseases journal.
Findings from the Review indicate that vector-borne diseases, which are transmitted by insects such as mosquitoes and ticks, are on the rise and have spread into new territories across Europe over the past decade (eg, malaria in Greece, West ...
A new study by researchers at Brigham and Women's Hospital (BWH) has found that for young, healthy women taking spironolactone to treat hormonal acne, frequent office visits and blood draws are an unnecessary health care expense. For the approximately 1,000 patients studied, blood tests to monitor potassium levels did not change the course of treatment, but the tests cumulatively totaled up to $80,000. The research team suggests that routine potassium monitoring should no longer be recommended for this patient population in order to improve the patient care experience, ...
DENVER, March 22, 2015 -- Taking vitamin D supplements could slow or even reverse the progression of less aggressive, or low-grade, prostate tumors without the need for surgery or radiation, a scientist will report today.
His team will describe the approach in one of nearly 11,000 presentations at the 249th National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society. The meeting is being held here through Thursday.
If a tumor is present in a prostate biopsy, a pathologist grades its aggressiveness on a scale known as ...
DENVER, March 22, 2015 -- Scientists will report in a presentation today that they have turned to the opossum to develop a promising new and inexpensive antidote for poisonous snake bites. They predict it could save thousands of lives worldwide without the side effects of current treatments.
The presentation will take place here at the 249th National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society. The meeting features nearly 11,000 reports on new advances in science and other topics. It is being held through Thursday.
Worldwide, ...